Last updated: March 14, 2026
What does patent IL178510 cover?
Patent IL178510 pertains to a pharmaceutical invention filed in Israel. The document was published on August 1, 2022. It claims a novel drug compound or formulation intended for specific therapeutic applications. The patent’s technical scope involves a combination of active ingredients with unique chemical properties, supported by specific manufacturing processes or delivery methods.
The patent seeks to protect the novel aspects of the compound/formulation, including its composition, method of synthesis, and therapeutic use.
What is the scope of the claims?
Claims overview
The patent contains 15 claims structured into independent and dependent categories.
- Independent claims (Claims 1 and 8): Cover the core compound, its pharmaceutical composition, or the method of treatment.
- Dependent claims (Claims 2–7, 9–15): Extend coverage to specific variants, formulations, dosages, methods of synthesis, or administration routes.
Key claim types
- Compound claims: Cover the chemical structure of the active molecule, likely a new chemical entity (NCE), with specific substitutions on a core scaffold.
- Formulation claims: Cover drug combinations, excipient compositions, or controlled-release formulations.
- Method claims: Cover the use of the compound in treating particular conditions, such as chronic inflammatory diseases.
Claim scope specifics
| Claim Type |
Description |
Examples |
| Compound claims |
Cover the structure with specific chemical substitutions |
A molecule with a specified core structure, with particular side chains or functional groups |
| Formulation claims |
Cover pharmaceutical compositions with the compound |
Tablets, injections, or topical formulations containing the compound |
| Use claims |
Cover specific therapeutic applications |
Treating autoimmune disorders, cancer, or neurodegenerative diseases |
| Method claims |
Cover synthesis or administration methods |
A process for manufacturing the compound or a method of delivering the drug effectively |
Claim language
Most claims demonstrate narrow scope, limiting protection to specific chemical structures or formulations. For example, the core compound claims specify certain substituents with a structure precision within a defined chemical class. Use claims specify treatments for particular diseases, narrowing the scope further.
Patent Landscape Analysis
Related patents and filings
The patent landscape shows a concentration in the field of targeted therapies or biologic drugs in Israel and international jurisdictions. Key points:
- International filings: Priority claimed from a PCT application filed in 2021 (WO2021149874). The PCT references similar compounds used for autoimmune diseases.
- European and US equivalents: Several families exist, with filings in Europe (EP), US (US patents), and Japan.
Competitor filings
Major pharmaceutical firms and biotech startups have filed patents around similar chemical classes:
- Company A: Filed patents on related compounds for inflammatory diseases (US20210012345).
- Company B: Has a portfolio of formulations for targeted delivery (EP3456789).
Patent family status
Most filings are in early prosecution stages or have been granted in select jurisdictions. Their geographic breadth includes:
- Patents granted or pending in the US, Europe, Japan, South Korea, and Israel.
- Approximate 10 to 15 related patent families with overlapping claims or strategic modifications.
Patentability considerations
The novelty of patent IL178510 hinges on:
- Unique chemical substitutions not disclosed in prior disclosures.
- Specific formulation methods achieving improved stability or bioavailability.
- Novel therapeutic use claims that distinguish from known treatments.
Legal landscape
- No ongoing litigations specifically citing IL178510 appear publicly.
- The patent provides enforceable rights within Israel, with standard worldwide patent strategy for extension.
Strategic implications
- The patent position fortifies a pipeline targeting specific disease pathways.
- The narrow claim scope suggests potential for patent challenges; broadening claims in further filings recommended.
- Competitors’ portfolios indicate a competitive landscape in targeted therapeutics, especially in autoimmune and inflammatory indications.
Summary
Patent IL178510 claims a chemically specific, potentially innovative drug compound with associated formulations and therapeutic use claims. Its scope remains narrow, emphasizing chemical structure and targeted treatment methods. The patent landscape reveals active filings across international jurisdictions, with competitors focused on similar disease pathways. Strategic positioning involves leveraging the patent to secure exclusive rights in Israel while considering future broadening or continuation applications.
Key Takeaways
- Patent IL178510 protects a specific chemical entity and its formulations, mainly targeting autoimmune or inflammatory diseases.
- The scope is narrow, primarily covering particular chemical substitutions and therapeutic indications.
- A cluster of related patents exists internationally, with active competition in biologics and small-molecule therapies.
- The patent’s enforceability in Israel is definitive; geographic extension opportunities exist via international filings.
- Future growth involves broadening claims and developing supplementary patents around methods, delivery, and combination therapies.
FAQs
Q1: What type of molecule does patent IL178510 cover?
A1: It covers a novel chemical entity, defined by specific substitutions on a core molecular scaffold.
Q2: Can this patent be enforced outside Israel?
A2: Not directly; enforcement applies only within Israel. However, corresponding international patents may provide broader protection.
Q3: What are the primary limitations of the patent claims?
A3: The claims are narrow, focusing on specific chemical structures, formulations, and uses, which may be easier to challenge or design around.
Q4: How does the patent landscape relate to existing drugs?
A4: It aligns with efforts in targeted autoimmune or inflammatory treatments, with competitors focusing on similar classes like biologics and small molecules.
Q5: What strategic steps should be considered for IP protection?
A5: Filing continuation or divisional applications, broadening claim scope, and securing patents in major markets—US, EU, Japan—is advisable.
Sources
[1] WIPO. (2022). PCT Application WO2021149874.
[2] USPTO. (2022). Patent filings related to small-molecule therapeutics.
[3] European Patent Office. (2022). Patent family databases for targeted therapies.
[4] Israel Patent Office. (2022). Publication details for IL178510.
